When you think of high blood pressure, lifestyle choices around nutrition or exercise may come to mind—not your hormones. But ...

AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for ...

Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease – RADNOR, Pa., May 18, 2026 (G ...

Aldosterone escape and non-ACE pathways for angiotensin II production may explain, at least in part, the continued high mortality rates in heart failure patients despite the advances made in ...

Heart failure with preserved ejection fraction (HFpEF) accounts for roughly half of all heart failure presentations and is characterised by normal or near‐normal left ventricular systolic function ...

Preliminary results show that the treatment may reduce strain on both the heart and kidneys.

Lorundrostat, a novel aldosterone synthase inhibitor, reduces blood pressure among patients with uncontrolled hypertension on at least two drugs, according to results from the phase II Target-HTN ...

New drug Baxdrostat lowers stubborn high blood pressure in difficult-to-treat patients, showing promising results in a global ...

Background Introduction of guideline-directed medical therapy (GDMT) has transformed the care of heart failure (HF) with ...

The symptoms of hyperkalemia begin with muscle weakness. As serum potassium levels rise, symptoms progress to more significant muscle twitching, weakness, nausea, and cramping. [69] Cardiac conduction ...